Myxedema coma and thyroid storm are rare thyroid emergencies with high mortality, requiring evidence of clinical decompensation in the setting of hypothyroidism or thyrotoxicosis for diagnosis. Urgent recognition, intensive supportive care, and rapid initiation of disease-specific therapy by a multidisciplinary team are critical for optimal outcomes.
- Yes
Managing TED in Practice: Expanding the Endocrinologist’s Scope
CME : 1 | MOC : 1
Starts 10/6/2025 | Expires 10/6/2026
This complimentary on-demand webinar is designed to help clinicians create a path to diagnosis when encountering a patient with thyroid eye disease.
- Yes
Paresthesia Muscle Spasms and Cramps: Unraveling the Hypocalcemia Puzzle in Hypoparathyroidism
CME : 1 | MOC : 1
Starts 10/13/2025 | Expires 10/13/2026
This complimentary on-demand webinar is designed to help clinicians create a path to diagnosis when encountering a patient with hypoparathyroidism.
- Yes
AACE Rare Diseases and Hormone Disorders 2025: Pathways to Diagnosis
CME : 6 | MOC : 6
Starts 10/3/2025 | Expires 10/3/2026
Register for our complimentary Rare Diseases and Hormone Disorders webinar series covering rare endocrine conditions and hormone disorders including: thyroid eye disease, hypoparathyroidism, homozygous familial hypercholesterolemia, severe hypertriglyceridemia, congenital adrenal hyperplasia, and polycystic ovary syndrome.
- No
CME : 6 | MOC : 6
December 10–11, 2025
Early Bird Registration Deadline Extended to 12/1/25
Join us virtually on December 10–11, 2025, to explore the newest AACE clinical guidance documents presented by the experts who created them. This two-evening virtual CME event covers evidence-based care in obesity, dyslipidemia, multiple endocrine neoplasia, and menopause management.
- No
CME : 47.25 | CE : 47.25
April 22–24, 2026
Register today with Early Bird prices for the AACE Annual Meeting taking place Wednesday through Friday, April 22–24, 2026, in Las Vegas, NV!
Call for Poster Abstracts
We invite you to submit an abstract and have the unique opportunity to showcase your work that will be reviewed by experts in the field of endocrinology. Deadline Dec. 1.
- No
AACE Annual Meeting 2025 On Demand
CME : 51.75 | MOC : 51.75
Starts 6/23/2025 | Expires 4/1/2026
Didn't make it to the AACE 2025 Annual Meeting? Access all the invaluable insights and groundbreaking discoveries with our on-demand session recordings.
$999 | Informed Member - $799 | Engaged Member - $599 | Fellow Member - $499
- No
Hands-On Thyroid Nodules Certificate
CME : 3 | MOC : 3
Starts: 7/28/2025 | Expires: 7/28/2027
This comprehensive online certificate program aims to provide endocrinologists and care team members with advanced training in the latest diagnostic and management strategies for thyroid conditions.
$295 | Informed Member - $235 | Engaged Member - $175 | Fellows $115
Clinical Guidance
2022 Consensus Statement on Minimally Invasive Procedures for Benign and Malignant Thyroid Lesions
This consensus statement provides information on novel minimally invasive therapeutic interventions for thyroid malignancies such as percutaneous ethanol injection and thermal ablation. The statement summarizes existing knowledge and provides guidance on indications, techniques, complications, and follow-ups for care of patients with benign and malignant thyroid lesions.
2021 Consensus Statement on Thyroid Nodule Algorithmic Tool
This consensus statement describes the Thyroid Nodule App (termed TNAPP), a novel interactive web-based tool that uses clinical, imaging, cytologic, and molecular marker data to guide clinical decision making to evaluate and manage thyroid nodules.
AvoMD Integrates AACE Guidelines
AvoMD, a software platform that brings clinical evidence into the workflow to help clinicians streamline decisions and save time, has partnered with AACE to integrate clinical guidance documents into the AvoMD platform.
Additional Resources
AACE Journey For Patients With Thyroid Disease
The AACE Journey for Patients With Thyroid Disease is a reliable resource to help your patients better understand and manage their condition. Developed from our clinical guidance documents and reviewed by the Thyroid Cancer Survivors’ Association (ThyCa), it provides accurate, patient-centered information.
Read More
Perspectives on Graves’ Disease Management: Challenges With the Current Treatment Paradigm
Watch our free on-demand webinar sponsored by Immunovant, Inc., to hear from clinical experts Mark Lupo, MD, founder and medical director of the Thyroid & Endocrine Center of Florida, and Giuseppe Barbesino, MD, of Massachusetts General Hospital, for a moderated discussion about the treatment landscape in Graves’ disease, which has remained largely unchanged for the last 70 years.
Read More
Understanding the Autoimmune Link Behind Graves’ Disease and Thyroid Eye Disease
Graves’ disease and Thyroid Eye Disease (TED) are closely linked autoimmune conditions driven by antibodies targeting the thyroid-stimulating hormone receptor. This article, sponsored by Immunovant, explores the role of the thyroid-stimulating hormone receptor (TSHR), the current treatment landscapes for both Graves’ disease and thyroid eye disease (TED), and the promise of emerging therapies that target the underlying autoimmune cause.
Learn More
Journal Articles
Thyroid Emergencies: A Narrative Review
Rapid Onset of Type 1 Diabetes Mellitus and Destructive Thyroiditis Following Immunotherapy for Metastatic Melanoma
This case emphasizes the need for vigilant monitoring of immune-related adverse events in patients receiving combination immune checkpoint inhibitors.
Hypocalcemia Post Total Thyroidectomy: A Ten-Year, Single Institution Experience with a PTH-Guided Calcium and Calcitriol Supplementation Protocol
A PTH-guided Ca and calcitriol supplementation protocol significantly reduces post-TT hypocalcemia and related readmissions and may represent a useful approach in managing suitable candidates for outpatient TT